Dexamethasone Tablets B.P. 0.5mg
Each uncoated tablet contains
Dexamethasone BP 0.5mg
Antineoplastic agents, Hormonal, GIucocorticoids, Antiemetics, Anti-inflammatory agents, adrenergic agents.
Dexamethosone is a glucocorticoid agent. Unbound dexamathasone crosses cell membranes and binds with high affinity to specific cytoplasmic receptors. This results in a modification of transcription and, hence, protein synthesis in order to achieve inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The anti-inflammatory actions of dexamethasone are thought to involve phospholipase A2 inhibitory proteins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
OM-D, corticosteroid drug, is used to reduce inflammation and relieve symptoms in a variety of disorders, including rheumatoid arthritis and severe cases of asthma. It may be given to people to treat primary or secondary adrenal cortex insufficiency (lack of sufficient adrenal hormone). It is also given to help treat the following disorders: Severe allergic conditions such as drug-induced, allergies, Blood disorders such as various anemias, Certain cancers (along with other drugs), Skin diseases such as severe psoriasis, Collagen (connective tissue) diseases such as systemic lupus erythematosus, Digestive tract disease such as ulcerative colitis, High serum levels of calcium associated with cancer, Fluid retention due to nephrotic syndrome (a condition in which damage to the kidneys causes the body to lose protein in the urine), Eye diseases such as allergic conjunctivitis, Lung diseases such as tuberculosis (along with other drugs).
ADULTS: Initial doses range from 0.75 milligram to 9 milligrams a day and or as prescribed by your doctors.
OM-D should not be used if you have a fungal infection, or if you are sensitive or allergic to any of its ingredients.
Amphotericin B & hydrocortisone: cardiac enlargement and congestive heart failure.
Atibiotics: decrease in corticosteroid clearance.
Anticholinesterases: produce severe weakness in patients with myasthenia gravis.
Antidiabetics: increase blood glucose concentrations.
Antitubercular drugs: Serum concentrations of isoniazid may be decreased.
Cholestyramine: increase the clearance of corticosteroids.
Cyclosporine: Convulsions have been reported with this concurrent use.
Digitalis glycosides: increased risk of arrhythmias due to hypokalemia.
Ketoconazole: increased risk of corticosteroid side effects.
Nonsteroidal anti-inflammatory agents (NSAIDS): Increases the risk of gastrointestinal side effects.
Phenytoin: in post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control.
Thalidomide: as toxic epidermal necrolysis has been reported with concomitant use.
Abdominal distention, allergic reactions, blood clots, bone fractures and degeneration, bruises, cataracts, congestive heart failure, convulsions, “cushingoid” symptoms (moon face, weight gain, high blood pressure, emotional disturbances, growth of facial hair in women) excessive hairlines, fluid and salt retention, general feeling of illness, glaucoma, headache, hiccups, high blood pressure, high blood sugar, hives, increased appetite, increased eye pressure, increased pressure in head, increased sweating, increases in amounts of insulin or hypoglycemic medications needed in diabetes, inflammation of the esophagus, inflammation of the pancreas, irregular menstruation, loss of muscle mass, low potassium levels in blood (leading to symptoms such as dry mouth, excessive thirst, weak or irregular heartbeat, and muscle pain or cramps), muscle weakness, nausea, osteoporosis, peptic ulcer, perforated small and large bowel, poor healing of wounds, protruding eyeballs, suppression of growth in children, thin skin, tiny red or purplish spots on the skin, torn tendons, vertigo and weight gain.
Oral, rat LD50: >3 gm/kg. Signs of overdose include retinal toxicity, glaucoma, subcapsular cataract, gastrointestinal bleeding, pancreatitis, aseptic bone necrosis, osteoporosis, myopathies, obesity, edemas, hypertension, proteinuria, diabetes, sleep disturbances, psychiatric syndromes, delayed wound healing, atrophy and fragility of the skin, ecchymosis, and pseudotumor cerebri.
The effects of OM-D during pregnancy have not been adequately studied.
Corticosteroids appear in breast milk and can suppress growth in infants. If OM-D is essential to your health, your doctor may advise you to stop breastfeeding until your treatment with this drug is finished.
Store below 25°C in a dry place. Protect from light & moisture.
KEEP OUT OF REACH OF CHILDREN
OM-D Tablets pack in Blister package of 10 x 10 Tablets.
ZADIP PHARMA NIG. LTD.
48B, Town Planning Way, llupeju, Lagos.
NEST LIFESCIENCE Pvt. Ltd.
Comed Chemicals Limited
359, Rania, Taluka-Sovil, District-Boroda, Gujarat, India.